US - HealthQuill

Abbott Laboratories has initiated a clinical trial to evaluate the use of the company's deep brain stimulation system to manage treatment-resistant depression, a form of major depressive disorder.

Abbott starts trial on deep brain stimulation for depressive disorder

Abbott Laboratories has initiated a clinical trial to evaluate the use of the company's deep brain stimulation system to manage treatment-resistant depression, a.

by HealthQuill
September 4, 2024
0 Comments

Eli Lilly will license manufacturing know-how of its rheumatoid arthritis baricitinib drug, branded as Olumiant, to Egypt’s EVA Pharma to expand its access to 49 nations in Africa.

Drugs Health Pharma

Eli Lilly to license rheumatoid drug-making technology to Egypt’s EVA

Eli Lilly will license manufacturing know-how of its rheumatoid arthritis baricitinib drug, branded as Olumiant, to Egypt’s EVA Pharma to expand its access to.

by HealthQuill
September 4, 2024
0 Comments

Emergent BioSolutions Inc., got the US drug regulator’s approval to expand its smallpox vaccine use to treat mpox, according to a company statement.

Drugs Health Pharma

Emergent gets US drug regulator’s nod to use its smallpox vaccine for mpox

Emergent BioSolutions Inc., got the US drug regulator’s approval to expand its smallpox vaccine use to treat mpox, according to a company statement.

by HealthQuill
September 1, 2024
0 Comments

McKesson Corporation, the ninth-largest company by revenue in the US, will acquire Community Oncology Revitalization Enterprise Ventures, for $2.4 billion in cash to expand its oncology portfolio.

Drugs Health Pharma

McKesson Corp., to acquire Core Ventures for $2.4 billion in cash

McKesson Corporation, the ninth-largest company by revenue in the US, will acquire Community Oncology Revitalization Enterprise Ventures, for $2.4 billion in cash to expand its.

by HealthQuill
August 27, 2024
0 Comments

Insulet Corporation, a tubeless insulin pump maker, got clearance from the US Food and Drug Administration to add diabetes type 2 adult patients 18 years or older, to the treatment regime.

Drugs Health Pharma

Regulator okays Insulet’s insulin pump in US to treat type 2 diabetes

Insulet Corporation, a tubeless insulin pump maker, got clearance from the US Food and Drug Administration to add diabetes type 2 adult patients.

by HealthQuill
August 27, 2024
0 Comments

Switzerland’s Basilea Pharmaceutica Ltd. will receive $1.25 million from its partner Pfizer Inc. after the latter exceeded the sales target for a licensed anti-fungal drug in the Asia-Pacific region and China.

Drugs Medical Pharma

Basilea Pharmaceutica to get $1.25m license fee from Pfizer

Switzerland’s Basilea Pharmaceutica Ltd. will receive $1.25 million from its partner Pfizer Inc. after the latter exceeded the sales target for a licensed.

by HealthQuill
August 21, 2024
0 Comments

Johnson & Johnson plans to acquire Israel’s privately-held V-Wave Ltd., for an upfront payment of $600 million, according to a statement from the US-based company.

Drugs Health Pharma

J&J plans to acquire Israel’s V-Wave by paying $600 million upfront

Johnson & Johnson plans to acquire Israel’s privately-held V-Wave Ltd., for an upfront payment of $600 million, according to a statement from the.

by HealthQuill
August 20, 2024
0 Comments

China’s drug regulator, the National Medical Products Association, has approved AstraZeneca Plc’s asthma drug.

Drugs Health Pharma

AstraZeneca’s asthma drug gets regulator’s approval in China

China’s drug regulator, the National Medical Products Association, has approved AstraZeneca Plc’s asthma drug.

by HealthQuill
August 20, 2024
0 Comments

Citius Pharmaceuticals, Inc., a US-based biotechnology company, got a green light from the country’s drug regulator for its immunotherapy treatment for a rare form of blood cancer that affects the skin.

Drugs Health Pharma

Citius’s blood cancer drug gets US regulatory body’s clearance

Citius Pharmaceuticals, Inc., a US-based biotechnology company, got a green light from the country’s drug regulator for its immunotherapy treatment for a rare.